메뉴 건너뛰기
Journal of Thrombosis and Thrombolysis
Volumn 28, Issue 1, 2009, Pages 74-76
Intracoronary bivalirudin for no reflow reversal: A second chance to treat this disorder?
Author keywords

Bivalirudin; Intracoronary drugs; No reflow
Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; NITROPRUSSIDE SODIUM; PLASMA SUBSTITUTE;
EID: 67449107598     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0243-9     Document Type: Article
Times cited : (9)
References (5)
  • 1
    • 33747763298 scopus 로고    scopus 로고
    • The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion
    • doi: 10.1007/s00395-006-0615-2
    • Reffelmann T, Kloner RA (2006) The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 101(5):359-372. doi: 10.1007/s00395-006-0615-2
    • (2006) Basic Res Cardiol , vol.101 , Issue.5 , pp. 359-372
    • Reffelmann, T.1    Kloner, R.A.2
  • 2
    • 34547888759 scopus 로고    scopus 로고
    • Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: A clinical scenario of ischemic preconditioning
    • doi: 10.1139/Y07-013
    • Parikh KH, Chag MC, Shah KJ, Shah UG, Baxi HA, Chandarana AH et al (2007) Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: A clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 85(3-4):476-482. doi: 10.1139/Y07-013
    • (2007) Can J Physiol Pharmacol , vol.85 , Issue.3-4 , pp. 476-482
    • Parikh, K.H.1    Chag, M.C.2    Shah, K.J.3    Shah, U.G.4    Baxi, H.A.5    Chandarana, A.H.6
  • 3
    • 33748072107 scopus 로고    scopus 로고
    • The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention
    • doi: 10.1136/hrt.2006.088427
    • Harding SA (2006) The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention. Heart 92(9):1191-1193. doi: 10.1136/hrt.2006.088427
    • (2006) Heart , vol.92 , Issue.9 , pp. 1191-1193
    • Harding, S.A.1
  • 4
    • 67449104579 scopus 로고    scopus 로고
    • http://www.angiomax.com/AboutAngiomax/dosingAdmin.aspx
  • 5
    • 33846517585 scopus 로고    scopus 로고
    • Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    • doi: 10.1586/14779072.5.1.57
    • Lewis BE, Hursting MJ (2007) Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 5(1):57-68. doi: 10.1586/ 14779072.5.1.57
    • (2007) Expert Rev Cardiovasc Ther , vol.5 , Issue.1 , pp. 57-68
    • Lewis, B.E.1    Hursting, M.J.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.